Shares of CG Oncology could soar from here, according to Guggenheim. The investment firm initiated coverage of the biopharma stock with a buy rating and $90 price target, which implies shares could surge 137% from their Tuesday close of $38. CG Oncology focuses on developing treatments for bladder cancer. The stock has popped 33% in 2025, outpacing the S & P 500's 14% during that time. Guggenheim analyst Brad Canino pointed to the company's solid position within the non-muscle invasive bladder cancer industry. He also applauded CG Oncology's development of cretostimogene, an oncolytic immunotherapy. "The nascent NMIBC drug market has lots of patients, industry pricing power, and long treatment durations, which makes the CGON story rise to the top of quality oncology ideas, in our view, given the best-in-class efficacy, durability and safety of cretostimogene, which will enter FDA review next year," he wrote. Canino continued: "These NMIBC patients undergo therapies to prevent invasive operations or bladder removal (cystectomy), which creates motivation to use the most durable product, such as cretostimogene. These patients also have a non-lethal form of cancer and demand a pristine drug safety profile, which we believe cretostimogene provides." The analyst added that CG Oncology offers a "potentially attractive catalyst path." This includes numerous data and regulatory updates across multiple segments into the next two years. Analysts are bullish on the stock, with all 12 of the ones covering it assigning a buy or strong buy rating, LSEG data shows. ( Learn the best 2026 strategies from inside the NYSE with Josh Brown and others at CNBC PRO Live. Tickets and info here . )
